i-FACTOR
-
Biologics
Cerapedics’ i-FACTOR P-15 Peptide Enhanced Bone Graft, a Trusted Choice in Bone Graft Solutions, Now Approved for Expanded Indications for Use
Approval underscores Cerapedics’ commitment to investing in evidence that brings scientific rigor to bone grafting for spinal fusion. WESTMINSTER, Colo., Sept.…
Read More » -
Biologics
Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery
Data published in ClinicoEconomics and Outcomes Research show that the novel i-FACTOR is not only cost-effective compared to autograft in…
Read More » -
Biologics
Cerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data
WESTMINSTER, Colo., Nov. 18, 2019 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has…
Read More » -
Biologics
Cerapedics Announces i-FACTOR™ Peptide Enhanced Bone Graft Adopted by More than 150 Leading U.S. Hospitals
WESTMINSTER, Colo., Oct. 26, 2017 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced that more than 150 leading U.S. hospitals have now…
Read More » -
Hospitals
Cerapedics Receives FDA Approval for i-FACTOR™ Peptide Enhanced Bone Graft in Cervical Spine Surgery
WESTMINSTER, Colo., Nov. 3, 2015 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, announced today the U.S. Food and Drug Administration (FDA) has approved…
Read More »